Drug intelligence / Profile preview

PD-L1 x VEGF-A

Development stage: Preclinical
Lead developer: BioNTech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Intratumoral, Intraperitoneal

Overview

PD-L1 x VEGF-A is a bispecific monoclonal antibody developed through a collaboration between Bristol Myers Squibb and BioNTech. This asset is designed to combine immune checkpoint blockade by targeting PD-L1 with anti-angiogenesis therapy by targeting VEGF-A, for the treatment of cancer.

Targets

VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on PD-L1 x VEGF-A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PD-L1 x VEGF-A.

Explore the full profile